Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Neurotoxicity of Paclitaxel and Rapamycin in a Rat Model with Transient Blood-Brain Barrier Opening

  • Cho, Won-Sang (Department of Neurosurgery, Seoul National University Hospital) ;
  • Choi, Jung Hoon (Department of Anatomy, College of Veterinary Medicine, Kangwon National University) ;
  • Kwon, O-Ki (Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • Received : 2021.04.01
  • Accepted : 2021.06.10
  • Published : 2022.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : Drug-eluting stents and balloons are occasionally used to reduce restenosis in medically intractable intracranial atherosclerotic stenosis. The authors aimed to determine whether such drugs can cause neurotoxicity due to local effects in a rat model. Methods : Intra-arterial catheters were placed in the right common carotid artery of rats. Mannitol was injected to transiently open the brain-blood barrier (BBB), followed by high-dose drug (paclitaxel and rapamycin) injection. The optimal time interval of transient BBB opening for maximal drug penetration was determined to be 10 minutes. Paclitaxel and rapamycin were intra-arterially administered in various doses. All the rats were neurologically evaluated, and their brain tissues were histologically examined. Results : Neither neurological deficits nor histological abnormalities were observed in all the rats. Conclusion : Paclitaxel and rapamycin did not cause neurotoxicity in a rat model with transient BBB opening.

Keywords

Acknowledgement

This study was supported by a fund (02-2017-18) from Seoul National University Bundang Hospital.

References

  1. Abou-Chebl A, Bashir Q, Yadav JS : Drug-eluting stents for the treatment of intracranial atherosclerosis: initial experience and midterm angiographic follow-up. Stroke 36 : e165-e168, 2005
  2. Barnard ZR, Alexander MJ : Update in the treatment of intracranial atherosclerotic disease. Stroke Vasc Neurol 5 : 59-64, 2019 https://doi.org/10.1136/svn-2019-000279
  3. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H : Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17 : 472-476, 1986 https://doi.org/10.1161/01.STR.17.3.472
  4. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. : Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365 : 993-1003, 2011 https://doi.org/10.1056/NEJMoa1105335
  5. Gheith O, Cerna M, Halim MA, Nampoory N, Al-Otaibi T, Nair P, et al. : Sirolimus-induced combined posterior reversible encephalopathy syndrome and lymphocytic pneumonitis in a renal transplant recipient: case report and review of the literature. Exp Clin Transplant 15(Suppl 1) : 170-174, 2017
  6. Gupta R, Al-Ali F, Thomas AJ, Horowitz MB, Barrow T, Vora NA, et al. : Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke 37 : 2562-2566, 2006 https://doi.org/10.1161/01.str.0000242481.38262.7b
  7. Kim J, Ban SP, Kim YD, Kwon OK : Long-term outcomes of drug-eluting stent implantation in patients with symptomatic extra- and intracranial atherosclerotic stenoses. J Cerebrovasc Endovasc Neurosurg 22 : 216-224, 2020 https://doi.org/10.7461/jcen.2020.E2020.09.001
  8. Kim SJ, Kim YJ, Ko JH : Long term outcome of in-stent stenosis after stent assisted coil embolization for cerebral aneurysm. J Korean Neurosurg Soc 62 : 536-544, 2019 https://doi.org/10.3340/jkns.2019.0087
  9. Levy EI, Hanel RA, Howington JU, Nemes B, Boulos AS, Tio FO, et al. : Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response. J Neurosurg 100 : 688-694, 2004 https://doi.org/10.3171/jns.2004.100.4.0688
  10. Levy EI, Hanel RA, Tio FO, Garlick DS, Bailey L, Cunningham MR, et al. : Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment. Neurosurgery 59 : 925-933; discussion 933-934, 2006 https://doi.org/10.1227/01.NEU.0000233777.46522.1E
  11. Maramattom BV, Wijdicks EF : Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Neurology 63 : 1958-1959, 2004 https://doi.org/10.1212/01.WNL.0000144351.63740.81
  12. Park S, Lee DG, Chung WJ, Lee DH, Suh DC : Long-term outcomes of drug-eluting stents in symptomatic intracranial stenosis. Neurointervention 8 : 9-14, 2013 https://doi.org/10.5469/neuroint.2013.8.1.9
  13. Qureshi AI, Kirmani JF, Hussein HM, Harris-Lane P, Divani AA, Suri MF, et al. : Early and intermediate-term outcomes with drug-eluting stents in high-risk patients with symptomatic intracranial stenosis. Neurosurgery 59 : 1044-1051; discussion 1051, 2006 https://doi.org/10.1227/01.neu.0000245593.54204.99
  14. Reagan-Shaw S, Nihal M, Ahmad N : Dose translation from animal to human studies revisited. FASEB J 22 : 659-661, 2008 https://doi.org/10.1096/fj.07-9574lsf
  15. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC : Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 20(4 Suppl 3) : 1-15, 1993
  16. Steinfort B, Ng PP, Faulder K, Harrington T, Grinnell V, Sorby W, et al. : Midterm outcomes of paclitaxel-eluting stents for the treatment of intracranial posterior circulation stenoses. J Neurosurg 106 : 222-225, 2007 https://doi.org/10.3171/jns.2007.106.2.222
  17. Velasco R, Bruna J : Taxane-induced peripheral neurotoxicity. Toxics 3 : 152-169, 2015 https://doi.org/10.3390/toxics3020152
  18. Waksman R, Pakala R : Drug-eluting balloon: the comeback kid? Circ Cardiovasc Interv 2 : 352-358, 2009 https://doi.org/10.1161/CIRCINTERVENTIONS.109.873703